Jump to content

Stocks more likely to make profit in footsie 100


Recommended Posts

So far I have not heard any one for Stocks more likely to rise in value and make profit in 2018.

My own view is that Footsie won't go far this year. If not crash but stay 5% to 10% in the range ,what it is at the moment.

My own recommendation for this year for stocks is

1. Legal & General  

2. Sophos

3  GSK

Number 1 & 3 is also more for the Dividends And No 3 is more for the future danger of Cyber attacks

I would like to hear from others their views .

Peter77

Link to comment

Peter,

 

its good to hear some suggestions. For LGEN I note this has a yield of 5.3%, which seems reasonable. I looked at a FTSE 100 table and this yield makes LGEN the 12th highest paying FTSE100 stock, based on this value. Interestingly I hold Imperial Brands, which is the 11th highest payer at 5.4% and I too bought this for the yield alone, so in a sense we have both reached the same decision. With IMB I am expecting capital growth over the next 12 months because a) it is a defensive stock and b) the price has come down from a high of around £41.30 reached in 2017. I expect this correction to be reversed and IMB are investing in new products to protect their market share.

 

I don't however know much about Legal and General!

 

In respect of Sophos, this is not a FTSE100 constituent so not sure if that affects your decision making (it initially looked like you were trying to identify FTSE100 stocks to out perform the index?) I don't know much about it except the stock has roughly doubled over the last 12 months, so it would be a great feat if it were to do that again. (Do you know anything about the company its prospects or its products, btw?) it is on a very punchy rating of f/c PER 121 which is roughly akin to OCADO - a stock that is widely believed to be over-valued. I suppose largely it depends if SOPHOS can meet its profit targets for the year. This only pays 0.6% yield, so I would not be buying it for income, and for me the rating is too punchy to justify buying it now, without doing more research. Perhaps you can write up some notes?

 

In terms of GSK, I do partially resonate your thinking, and in a similar vein to LGEN, this could be a good buy for the yield of 6.1%, but perhaps with a bounce in the share price too. Perhaps there is M&A potential here?

I have held this share before, and given the three you picked then GSK would be my preference as the dividend yield is the highest of the three with some chance of share price growth too.

(note the cover is < 1 so is there a risk the dividend could be cut or frozen?)

 

You may want to plot these shares again the FTSE100 and see how they have tracked it, re-basing for say two years.  There is a good piece of work that could be undertaken here.

 

 

 

 

Link to comment

Create an account or sign in to comment

You need to be a member in order to leave a comment

Create an account

Sign up for a new account in our community. It's easy!

Register a new account

Sign in

Already have an account? Sign in here.

Sign In Now
  • Posts

    • Sainsburys full year earnings and Unilever’s first quarter trading update both say the same thing, UK consumers are in for higher prices. The war in Ukraine, supply chain issues and the effects of ongoing Covid all to blame.      
    • US Dollar (DXY) Daily Price and Analysis US Q1 GDP may stall the greenback’s advance. A 20-year high nears for the US dollar. The multi-month US dollar rally continues with the greenback printing a fresh high today ahead of the first look at US Q1 GDP at 12.30 GMT. The US dollar basket (DXY) has been boosted by renewed weakness in the Euro and the Japanese Yen, as investors move from lower-yielding to higher-yielding currencies, while safe-haven flows continue to benefit the greenback. The US growth release later in the session is expected to show a sharp slowdown from the robust Q4 figure of 6.9%. The markets are currently pricing in growth of just 1% for the first three months of this year, with the slowdown mainly due to a reduction in inventory accrual over the quarter. This release is unlikely to move the greenback, unless there is a large miss or beat, as the Fed believe that 2022 US growth will be robust enough to let them tighten monetary policy sharply without damaging the economy. The latest US Core PCE data – the Fed’s preferred inflation reading – is released on Friday and this may have more effect on the US dollar than today’s GDP data. For all market moving economic data and events, see the DailyFX Calendar. The ongoing US dollar rally has been aided by weakness across a range of G7 currencies including the Euro, the Japanese Yen, and the British Pound. The Euro continues to battle with lowly growth expectations, exacerbated by energy concerns, the British Pound is mired by weak economic data, while the Japanese Yen is in freefall as the BoJ continues with its ultra-loose monetary policy.   The US dollar continues to press higher and looks set to break above 103.96, the March 2020 high. Above here the US dollar would be back at levels last seen nearly two decades ago. The March resistance will likely hold in the short-term, especially with month-end portfolio rebalancing at the end of the week, but US dollar strength is set to continue in the months ahead. USDOLLAR (DXY) WEEKLY PRICE CHART – APRIL 28, 2022 {{THE_FUNDAMENTALS_OF_BREAKOUT_TRADING}} What is your view on the US Dollar – bullish or bearish?   Apr 28, 2022 | DailyFX Nick Cawley, Strategist
    • While Tesla has nothing directly to do with Elon Musk buying Twitter - TSLA stock closed down 12% on news that Musk may have to sell stock and use other holdings to stand against the loan to finalise the purchase of the social media giant.        
×
×
  • Create New...